key: cord-0268043-14rj0h9z
authors: Palliyil, Soumya; Mawer, Mark; Alawfi, Sami A; Fogg, Lily; Tan, Tyng H; De Cesare, Giuseppe Buda; Walker, Louise A; MacCallum, Donna M; Porter, Andrew J; Munro, Carol A
title: Monoclonal antibodies targeting surface exposed epitopes of Candida albicans cell wall proteins confer in vivo protection in an infection model
date: 2021-09-29
journal: bioRxiv
DOI: 10.1101/2021.09.29.462385
sha: 383bdf2616fbd1b8acfd2e60e680aad2ded819eb
doc_id: 268043
cord_uid: 14rj0h9z

MAb based immunotherapies targeting systemic and deep-seated fungal infections are still in their early stages of development with currently no licensed antifungal mAbs available for patients at risk. The cell wall glycoproteins of Candida albicans are of particular interest as potential targets for therapeutic antibody generation due to their extracellular location and key involvement in fungal pathogenesis. Here we describe the generation of recombinant human antibodies specifically targeting two key cell wall proteins (CWPs) in C. albicans - Utr2 and Pga31. These antibodies were isolated from a phage display antibody library using peptide antigens representing the surface exposed regions of CWPs expressed at elevated levels during in vivo infection. Reformatted human-mouse chimeric mAbs preferentially recognised C. albicans hyphal forms compared to yeast cells and an increased binding was observed when the cells were grown in the presence of the antifungal agent caspofungin. In J774.1 macrophage interaction assays, mAb pre-treatment resulted in a faster engulfment of C. albicans cells suggesting a role of the CWP antibodies as opsonising agents during phagocyte recruitment. Finally, in a series of clinically predictive, mouse models of systemic candidiasis, our lead mAb achieved an improved survival (83%) and several log reduction of fungal burden in the kidneys, similar to levels achieved for the fungicidal drug caspofungin, and superior to any anti-Candida mAb therapeutic efficacy reported to date.

Invasive fungal infections (IFIs) are serious, life-threatening conditions typically affecting 44 individuals with a compromised immune system including patients with haematological 45 malignancies, those undergoing cytotoxic chemotherapy and organ transplantation (1) .

Antigen design for recombinant antibody generation 141 Guided by the cell wall proteome analysis of various caspofungin susceptible and resistant 142 strains of C. albicans, peptide sequences accessible to trypsin digestion were identified and 143 matched with their respective fungal cell wall proteins (Tables 1A and 1B) (22) . Based on the 144 predicted β turn structures (algorithm NetTurnP 1.0) and hydropathy of these surface exposed 145 regions, peptide sequences were selected as antigens representing the CWPs Utr2 and Pga31. β 146 turn regions are often solvent exposed secondary structures and tend to have a relatively higher 147 propensity for antibody binding (29) . A small panel of trypsin-susceptible peptides from both 148 proteins were custom synthesised and C terminally biotinylated via an additionally introduced 149 lysine residue and these conjugates used as antigens for biopanning experiments. The antigen binding of top four Utr2 specific scAbs 1B1, 1D2, 1F4 and 1H3, selected based on 208 peptide-biotin conjugate ELISA signals, was confirmed ( Fig. 2A ) and these clones were tested 209 for their ability to recognise Utr2 in cell lysate preparations of C. albicans SC5314 yeasts (Fig.   210 2B). A non-specific negative control scAb was unable to bind to C. albicans cell lysate (Fig.   211 2B). The surface exposure and epitope accessibility of the Utr2 antigen peptide was established, 212 with all scAbs binding to C. albicans hyphal cells (Fig. 2C ). When yeast cells were treated with 213 0.032 µg/ml caspofungin, an increase in scAb binding was observed when compared to fungal 214 cells grown in the absence of the drug (Fig 2D-F) . No scAb binding was seen when the C. were confirmed by antigen binding ELISA with no cross-reactivity observed to unrelated peptide 261 sequences ( Fig. 3A & 3B ). MAb 1H3, which was selected against the Utr2 peptide, appeared to 262 also recognise a peptide sequence selected as a surface exposed region from the C. albicans cell 263 wall protein Phr2 (Fig. 3C ). The reason for this is unclear.

The conversion of scAbs into a bivalent IgG format significantly increased (possibly in part via 265 avidity) the relative binding affinities of all three lead antibodies. Their EC 50 values (antibody 266 concentration required to achieve 50% reduction in maximum absorbance) were calculated by In a whole cell binding ELISA, Pga31 mAb 1B11 preferentially recognise wild type C. albicans 275 (SC5314) hyphae compared to the yeast form (Fig. 3D) , suggesting a morphology dependent 276 binding function which could signify increased epitope accessibility in this phenotype. Although relatively poor binding activity was observed for the yeast form, when the cells were stressed 278 with caspofungin treatment, an enhancement in mAb targeting was seen (Fig. 3D ). 1H3 and 1D2 279 mAbs were able to bind SC5314 cells immobilised on maxisorbant plates ( Fig. 3E and 3F ), 280 however similar to Pga31 mAb 1B11, Utr2 mAbs were also seen to display increased binding 281 activity for the hyphae when compared to the yeast cells. Immunofluorescence staining of C. albicans using Utr2 and Pga31 antibodies 312 Immunofluorescent microscopy using cell wall protein specific antibodies 1D2, 1H3 and 1B11 313 demonstrated specific and distinct binding patterns on C. albicans cells. Antibodies 1B11 (anti-314 Pga31) and 1D2 (anti-Utr2) bound to C. albicans SC5314 hyphae but exhibited little or no 315 binding to mother yeast cells (Fig. 4) . 1D2 staining was visible across the entire hyphal surface, 316 whereas 1B11 showed more punctate binding in distinct hyphal regions (Fig. 4A) . The cross-317 reactive 1H3 mAb (anti-Utr2), appeared to bind specifically to the apical tip of growing hyphae 318 ( Fig 4A) . When C. albicans SC5314 yeast cells were stained using anti-Utr2 and anti-Pga31 The length of intracellular hyphae at multiple incubation times was also analysed from 

Comparing the percentage weight change (day 0-2, supplementary Table S1 ) and kidney fungal 463 burdens (Fig. 6B ), the differences were again statistically significant between some groups (P Fig. 6 when compared to the isotype control group (Pga31 mAb = 5.5. log 10 CFU/g vs isotype control = 503 6.8 log 10 CFU/g); however, there was little or no difference in mean fungal counts for the Utr2 504 mAb group (Utr2 mAb = 6.7 log 10 CFU/g vs isotype control = 6.8 log 10 CFU/g) (Table 3) . 505 Similarly, fungal burden in associated organs including the brain and spleen was also reduced in white and caspofungin (12). In our study a marked increase in Pga31 binding was also observed 598 when cells were treated with caspofungin ( Fig 4B) .

The ability of J774.1 macrophages to engulf C. albicans cells treated with CWP specific mAbs 600 or an isotype control anti-Candida mAb was significantly higher than non-antibody treated cells 601 (Table 2) . A complex interplay between macrophage and C. albicans has been previously 602 reported, with the pathogen sometimes counteracting the macrophage's defence strategies to 603 eventually break free and kill the macrophage as it escapes (36) . In our study, whilst the 

Mice were monitored and weighed every day during the course of experiments and at the end of 819 study period, mice were culled by cervical dislocation and organs, including kidneys, spleen and 820 brain, were removed aseptically and used to determine fungal burdens by plating out organ 821 homogenates and counting colonies after 24 h growth at 30°C.

In survival studies, mice which lost more than 20% of their initial body weight and/or showed represents mean change in body weight ± SD (g) at day 2 compared with day 0 in mouse study 1.

Global and Multi-National Prevalence 836 of Fungal Diseases-Estimate Precision

The Fungal Cell Wall: Structure, Biosynthesis, and 856 Function

A drug-sensitive genetic network masks fungi from the immune 858 system

Fungal Cell Wall Proteins and Signaling Pathways Form a 860

Retention of Saccharomyces cerevisiae cell wall proteins through a 863 phosphodiester-linked beta-1,3-/beta-1,6-glucan heteropolymer

Functional analysis of Candida albicans GPI-anchored 867 proteins: roles in cell wall integrity and caspofungin sensitivity

Genome-wide identification of fungal GPI 870 proteins

Molecular organization of the cell 872 wall of Candida albicans and its relation to pathogenicity

Monoclonal Antibodies as Tools to Combat Fungal Infections

An expanded cell wall damage signaling network is comprised of the 877 transcription factors Rlm1 and Sko1 in Candida albicans

Assembly of the yeast cell 879 wall. Crh1p and Crh2p act as transglycosylases in vivo and in vitro

The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a 883 predicted transglycosidase domain affects cell wall organization and virulence of Candida 884 albicans

CRZ1, a target of 886 the calcineurin pathway in Candida albicans

Identification of potential cell-surface proteins in Candida 889 albicans and investigation of the role of a putative cell-surface glycosidase in adhesion and 890 virulence

Candida albicans white 892 and opaque cells undergo distinct programs of filamentous growth

Caspofungin Induced Cell Wall Changes of Candida Species 895

Transcriptional profiling of putative glycosylphosphatidylinositol anchored 897 protein genes in Candida albicans. Unpublished raw data

Bispecific antibodies: a 899 mechanistic review of the pipeline

Unlocking the potential of antibody-drug conjugates 901 for cancer therapy

Combination immunotherapy of MAb B6.1 with fluconazole 903 augments therapeutic effect to disseminated candidiasis

Single human 906 B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against 907 disseminated candidiasis

The 910 monoclonal antibody Ca37, developed against Candida albicans alcohol dehydrogenase, inhibits 911 the yeast in vitro and in vivo

NetTurnP--neural network prediction of beta-913 turns by use of evolutionary information and predicted protein sequence features

Escherichia coli skp chaperone coexpression improves solubility 916 and phage display of single-chain antibody fragments

Monoclonal antibodies as anti-918 infective products: a promising future?

Carbon source-induced reprogramming of the cell wall proteome and 924 secretome modulates the adherence and drug resistance of the fungal pathogen Candida 925 albicans

Surface stress induces a conserved cell wall stress response in the 928 pathogenic fungus Candida albicans

Candida albicans and their role in fitness and virulence

I want to break free -macrophage 932 strategies to recognize and kill Candida albicans, and fungal counter-strategies to escape

Novel mouse monoclonal antibodies specifically 937 recognizing beta-(1-->3)-D-glucan antigen

Preliminary Characterisation of NP339, a Novel Polyarginine 940

Strategic approaches to optimizing peptide ADME properties

Therapeutic peptides: Historical perspectives, current development 944 trends, and future directions

Clinical pharmacokinetics of 946 therapeutic monoclonal antibodies

Multidrug-Resistant Candida: Epidemiology, Molecular 948 Mechanisms, and Treatment

Drug-Data and materials availability: All data are available in the main text or the supplementary 995 materials

Monoclonal antibodies targeting surface exposed epitopes of Candida albicans 1006 cell wall proteins confer in vivo protection in an infection model 1007

Corresponding authors: Soumya Palliyil, soumya.palliyil@abdn.ac.uk, Carol A Munro, 1009 c.a.munro@abdn.ac.uk 1010 1011 LIST OF SUPPLEMETARY MATERIALS contact verses the percentage of uptake events are plotted. (A) wt (B) Pga31 mAb (C) Utr2 mAb 1025 (D) positive control murine mAb. The rate of engulfment of all antibody-treated cells was faster 1026 than that of untreated C. albicans. Bars represent the percentages of uptake events